x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

From Concept to Medicine - A Comprehensive Drug Development Journey

Welcome to a Complete Drug Development Journey!Have you ever wondered how groundbreaking medicines go from a scientist’s vision to life-saving treatments in hospitals and pharmacies worldwide? The journey of drug development is an intricate, high-stakes adventure—filled with scientific breakthroughs, regulatory twists, and the relentless pursuit of innovation.In this podcast, we take you behind the scenes of pharmaceutical research and development, unraveling the complex and fascinating process that

science chemistry

All Episodes

14:43

70 - Labeling, Risk Management, and REMS (S5E10)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode delves into the crucial role of drug labeling, risk management plans, and REMS (Risk Evaluation and Mitigation Strategies) in ensuring safe post-approval drug use. We discuss the essential information contained in drug labels, including dosage instructions, expiration dates, and potential side effects, and how labels serve as evolving safety bulletins that are updated as new information emerges. We explore the proactive nature of risk management plans, which aim to anticipate and

en

12:11

69 - Advisory Committees & Public Hearings (S5E9)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode examines the role of advisory committees and public hearings in shaping drug approval and labeling decisions. We discuss the composition and function of advisory committees, highlighting the importance of their independent expertise in providing objective evaluations of new drugs. We explore the process of how these committees review data, hear presentations, and ultimately vote on whether to recommend a drug for approval. We also delve into the role of public hearings in providing a

en

17:54

68 - Regulatory Review: What the FDA Expects (S5E8)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode focuses on understanding the expectations of the FDA during the regulatory review process for new drug applications. We explore the key data points and presentation formats that meet these expectations, highlighting the importance of clearly demonstrating the drug's safety and effectiveness. We delve into the concepts of pharmacokinetics (PK) and pharmacodynamics (PD) and how they provide crucial information about the drug's behavior in the body. We discuss the importance of

en

15:14

67 – NDA/BLA Submission Process (S5E7)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode outlines the crucial process of compiling and submitting data to regulatory agencies, such as the FDA, following the completion of Phase 3 clinical trials. We explain the differences between the New Drug Application (NDA) for traditional small-molecule drugs and the Biologics License Application (BLA) for complex biologic therapies. We break down the structure and content of the electronic Common Technical Document (eCTD), the globally standardized format for regulatory submissions, and

en

23:37

66 – Phase 3 Success: A Case Study (S5E6)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode presents a detailed case study of a successful Phase 3 clinical trial, providing a real-world example of how meticulous planning and execution can lead to positive outcomes. We explore the critical elements of trial design, including the development of a clear hypothesis, sample size calculation, and the selection of appropriate endpoints. We discuss the challenges researchers face during trial execution and the importance of adhering to good clinical practice (GCP) to ensure data

en

14:54

65 - Managing Adverse Events in Large Trials (S5E5)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode focuses on the critical systems for monitoring, reporting, and managing adverse events in large, multicenter clinical trials. We define adverse events and discuss the challenges of accurately identifying and assessing them, especially in complex conditions like cancer. The importance of standardized reporting using tools like the NCI Common Toxicity Criteria (CTC) is highlighted. We explore the roles and responsibilities of various stakeholders, including research sponsors,

en

24:21

64 - Global Clinical Trials & Coordination (S5E4)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode explores the complexities of conducting clinical trials on a global scale, examining the challenges of coordinating research sites across diverse regions. We discuss the intricate regulatory landscape, with each country having its own set of rules and procedures, and the efforts towards harmonization through organizations like the ICH. The logistical hurdles of managing multinational trials, including shipping investigational drugs and biological samples across borders, are also

en

14:59

63 - Statistical Considerations in Phase 3 (S5E3)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode takes a deep dive into the advanced statistical methods employed in Phase 3 clinical trials, examining the concepts of statistical power and significance. We explore the factors that determine a trial's power, including sample size, treatment effect size, and data variability, and how these factors are intertwined in the sample size calculation process. We discuss the role of randomization and how it helps to minimize bias by ensuring balanced treatment groups. The concept of the

en

11:22

62 - Designing Robust Phase 3 Studies (S5E2)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode delves into the meticulous design principles behind robust Phase 3 clinical trials, exploring the elements that ensure statistical rigor and reliable endpoints. We discuss the critical roles of randomization and control groups in minimizing bias and providing a reliable benchmark for evaluating treatment effectiveness. We also explore different trial designs, such as parallel arm, factorial, and crossover designs, and their implications for data analysis. We examine the significance of

en

10:57

61 - Phase 3 - Large-Scale Efficacy Trials Overview...

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/14

This episode delves into the critical world of Phase 3 clinical trials, emphasizing their significance in drug development. We explore the core objectives of Phase 3, focusing on large-scale efficacy testing, diverse patient populations, and long-term safety evaluations. We discuss how these trials build upon earlier phases, shifting from preliminary findings to robust proof of a drug's effectiveness and safety profile. Real-world examples from landmark studies are used to illustrate the impact of

en

16:16

60 - Season 4 Recap & Bridging to Later Phases (S4E15)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode serves as a recap of the key lessons learned throughout Season 4, focusing on the crucial insights gained from Phase 1 and 2 clinical trials. We revisit the essential concepts of safety assessment, pharmacokinetics (PK), pharmacodynamics (PD), and dose escalation, emphasizing their importance in laying the foundation for larger, confirmatory Phase 3 trials. The episode highlights the dynamic nature of early-phase trials and the need for adaptive protocols to respond to emerging data and

en

15:44

59 – Real-World Examples (S4E14)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode delves into real-world case studies of innovative early clinical trial designs, highlighting the practical applications of adaptive methodologies. We explore examples of how these designs have been used to optimize dose finding, refine patient populations, and address challenges related to immunogenicity in biologics. The episode features a discussion of a historical study on chemotherapy trials for gastrointestinal cancer, which highlighted the limitations of traditional rigid trial

en

15:15

58 – Communication with Regulators in Early Trials...

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode focuses on best practices for proactive communication with regulatory agencies, such as the FDA and ICH, during early-phase clinical trials. We discuss the importance of early and open communication in building a strong relationship with regulators and gaining clarity on their expectations. The episode provides practical tips for researchers on how to effectively communicate with agencies, emphasizing the need for clear, concise, and data-driven submissions. We explore strategies for

en

19:33

57 - Data Analysis in Early Trials (S4E12)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode explains the statistical methods used to analyze data from Phase 1 and 2 clinical trials. We discuss how researchers interpret initial signals from these early studies, focusing on safety and tolerability in Phase 1 and efficacy in Phase 2. The episode covers key concepts like statistical power, clinical significance, and the importance of control groups in assessing drug efficacy. Common statistical models, such as t-tests, ANOVA, and logistic regression, are introduced, along with

en

23:32

56 - Monitoring Safety and Efficacy in Phase 2 (S4E11)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode examines the monitoring systems used in Phase 2 clinical trials to track safety and early efficacy signals. We discuss the various types of data collected, including adverse events, vital signs, lab results, and patient-reported outcomes. The importance of consistent and standardized data capture methods, including the use of electronic data capture (EDC) systems, is highlighted. We explore the role of data safety monitoring boards (DSMBs) and ethics committees in overseeing trial

en

17:25

55 - Patient Recruitment & Ethics in Early Trials...

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode focuses on the crucial aspects of patient recruitment and ethical considerations in early-phase clinical trials. We discuss various strategies for recruiting participants, emphasizing the importance of selecting appropriate research centers and utilizing various outreach methods. The ethical cornerstone of informed consent is explored in detail, highlighting the researchers' responsibility to clearly explain potential risks and benefits to participants. The discussion also covers the

en

14:54

54 - Adaptive Designs in Early Trials (S4E9)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode explores the innovative concept of adaptive trial designs in early-phase clinical trials, focusing on how these designs improve efficiency by allowing modifications based on interim data. We explain how adaptive designs differ from traditional fixed designs, offering greater flexibility and the ability to learn as the trial progresses. Several adaptive features are discussed, including dose adjustments, sample size adjustments, treatment selection, patient population enrichment, and

en

13:20

53 - Biomarkers in Phase 2 Trials (S4E8)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode focuses on the crucial role of biomarkers in Phase 2 clinical trials. Biomarkers, which are measurable indicators of biological processes or drug responses, are used to monitor drug response, predict clinical efficacy, and guide treatment decisions. We discuss various types of biomarkers, including those measuring protein levels, genetic signatures, and changes in physiological parameters like blood pressure. The episode emphasizes the importance of validating biomarkers, ensuring their

en

19:55

52 – Phase 2 Trial Design & Endpoints (S4E7)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode delves into the specifics of Phase 2 trial design, emphasizing the critical role of clinical endpoints in assessing a drug's efficacy. We discuss the importance of control groups, randomization, and blinding in minimizing bias and ensuring the reliability of the results. The different types of endpoints, including hard clinical endpoints like overall survival and surrogate endpoints like tumor shrinkage, are explained with real-world examples. The concept of statistical power, the

en

22:23

51 - Transitioning to Phase 2 - Efficacy Focus (S4E6)

From Concept to Medicine - A Comprehensive Drug... ·

2025/04/06

This episode explains the transition from Phase 1 safety trials to Phase 2 efficacy assessments in drug development. We explore how the focus shifts from primarily assessing safety to evaluating whether the drug actually works in patients with the specific condition it's designed to treat. The discussion covers the concept of efficacy endpoints, which are specific, measurable outcomes that reflect the desired effect of the drug. Examples include tumor shrinkage in cancer trials and blood sugar

en

270 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter